March 20, 2023

Cerevance to Present at AD/PD™ 2023 International Conference

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

  • Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
  • Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
  • Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed

Boston, MA – March 20, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present two symposium oral presentations and a poster presentation at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Gothenburg, Sweden, March 28 –April 1, 2023.

The first symposium oral presentation details the power of the NETSseq platform to generate highly reproducible molecular profiles from specific neuronal and glial cell types from the human brain. This data is being harnessed to identify and select novel targets for drug discovery, like KCNK13, which has the potential to result in life changing therapeutics for Alzheimer’s disease (AD)and other diseases.

Presentation details

Title: NETSseq Reveals Deep Molecular Insights Into Alzheimer’s Disease Progression and Facilitates Identification of Novel Therapeutic Targets

Presenter: Xiao Xu, PhD

Session Date and Time: Friday, March 31, 2023, 8:40-10:40am

Session Title: Exploring New Targets in AD, FTD, PD, and LBD

The second symposium oral presentation will describe data from the Phase 2 clinical trial of CVN424, a novel, non-dopaminergic, GPR6 inverse agonist. CVN424 has demonstrated the potential ability to provide benefit on par with dopamine therapies without any of the untoward side effects. In the 136-patient Phase 2 study,CVN424 also demonstrated an improvement in motor fluctuations and represents a potentially transformative therapy for patients with Parkinson’s disease (PD).

Presentation details

Title: CVN424,A Novel GPR6 Inverse Agonist Demonstrates Efficacy in an Adjunctive Parkinson’sDisease Phase 2 Clinical Trial

Presenter: Karl Kieburtz, MD, MPH

Session Date and Time: Saturday, April 1, 2023, 2:45-4:45pm

Session Title: Advances in PD and LBD Diagnosis and DrugDevelopment

The company will also present a poster session characterizing CVN417, a novel and selective modulator of neuronal acetylcholine receptor subunit alpha-6 (nAChR⍺6). Using the NETSseq platform, nAChR⍺6 expression has been shown to be selectivity enriched in PD-relevant dopaminergic neurons in humans. CVN417, which can modulate striatal dopamine release in rodents, has demonstrated efficacy in a rodent model of resting tremor and therefore may have therapeutic utility in PD.

Title: Characterization of CVN417: A Novel and Selective Nicotinic Alpha6 Receptor Antagonist for theModulation of Motor Dysfunction in Parkinson’s Disease

Presenter: Nicola Brice, PhD

Poster: P0823 /#734

Abstract: #393

About Cerevance

Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 136-patient Phase 2 study in patients withParkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq)platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease,Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit



Johnna Simoes,


Andrew Mielach,, +1-646-876-5868